Callan Family Office, LLC Fate Therapeutics Inc Transaction History
Callan Family Office, LLC
- $1.33 Trillion
- Q1 2025
A detailed history of Callan Family Office, LLC transactions in Fate Therapeutics Inc stock. As of the latest transaction made, Callan Family Office, LLC holds 82,024 shares of FATE stock, worth $82,844. This represents 0.0% of its overall portfolio holdings.
Number of Shares
82,024Holding current value
$82,844% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding FATE
# of Institutions
144Shares Held
96MCall Options Held
56.7KPut Options Held
5.4K-
Redmile Group, LLC San Francisco, CA12.9MShares$13 Million1.07% of portfolio
-
Vanguard Group Inc Valley Forge, PA10.3MShares$10.4 Million0.0% of portfolio
-
Black Rock Inc. New York, NY10.1MShares$10.2 Million0.0% of portfolio
-
Schonfeld Strategic Advisors LLC New York, NY7.79MShares$7.87 Million0.04% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il4.29MShares$4.33 Million0.0% of portfolio
About FATE THERAPEUTICS INC
- Ticker FATE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 97,000,304
- Market Cap $98M
- Description
- Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell...